LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 10 von insgesamt 34

Suchoptionen

  1. Artikel ; Online: In vitro fosfomycin study on concordance of susceptibility testing methods against ESBL and carbapenem-resistant Enterobacteriaceae.

    Aprile, Ausilia / Scalia, Guido / Stefani, Stefania / Mezzatesta, Maria Lina

    Journal of global antimicrobial resistance

    2020  Band 23, Seite(n) 286–289

    Abstract: Objectives: The increasing emergence and diffusion of multidrug-resistant (MDR) pathogenic bacteria, both in hospital and community settings, is inducing clinicians to reconsider old antibiotics, such as fosfomycin, to overcome the difficulties posed by ...

    Abstract Objectives: The increasing emergence and diffusion of multidrug-resistant (MDR) pathogenic bacteria, both in hospital and community settings, is inducing clinicians to reconsider old antibiotics, such as fosfomycin, to overcome the difficulties posed by these microorganisms. Recent studies have reported good in vitro activity of fosfomycin against extended spectrum ß-lactamases (ESBL) and carbapenem-resistant Enterobacteriaceae. The aim of this study was to assess thein vitro activity of fosfomycin by different methods against 120 clinical MDR isolates.
    Methods: Fosfomycin minimum inhibitory concentrations were determined using the agar dilution reference method (AD), gradient test (GT), broth microdilution method (BMD), according to CLSI recommendations, and automated systems (VITEK 2 and BD Phoenix) against 85 carbapenem-resistant Klebsiella pneumoniae and 35 ESBL-producing Escherichia coli. Agreement and discrepancies between the evaluated methods and the reference method were calculated.
    Results: Fosfomycin showed very good activity against ESBL-producing E. coli (88.6%). Excellent agreement (100%) between the three (AD, BMD and GT) susceptibility methods was found for E. coli. No major errors were observed. The fosfomycin resistance rate ranged from 24% (KPC-producing) to 100% (NDM-OXA-48 co-producing) K. pneumoniae. For all carbapenem-resistant K. pneumoniae strains, categorical agreement was >90% for all methods except for VITEK 2, which was 84%.
    Conclusions: When ESBL E. coli isolates are found to be susceptible to fosfomycin with automated systems, it is not necessary to verify these results with the AD reference method; while for resistant strains, the GT can be used. In cases of KPC K. pneumoniae resistant to fosfomycin, the AD method is the only reference method.
    Mesh-Begriff(e) Carbapenem-Resistant Enterobacteriaceae ; Escherichia coli ; Fosfomycin/pharmacology ; Klebsiella pneumoniae ; Microbial Sensitivity Tests
    Chemische Substanzen Fosfomycin (2N81MY12TE)
    Sprache Englisch
    Erscheinungsdatum 2020-10-09
    Erscheinungsland Netherlands
    Dokumenttyp Journal Article
    ZDB-ID 2710046-7
    ISSN 2213-7173 ; 2213-7165
    ISSN (online) 2213-7173
    ISSN 2213-7165
    DOI 10.1016/j.jgar.2020.09.022
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: Omic insights into various ceftazidime-avibactam-resistant

    Bongiorno, Dafne / Bivona, Dalida A / Cicino, Claudia / Trecarichi, Enrico M / Russo, Alessandro / Marascio, Nadia / Mezzatesta, Maria Lina / Musso, Nicolò / Privitera, Grete F / Quirino, Angela / Scarlata, Giuseppe G M / Matera, Giovanni / Torti, Carlo / Stefani, Stefania

    Frontiers in cellular and infection microbiology

    2023  Band 12, Seite(n) 1010979

    Abstract: Ceftazidime-avibactam (CZA) is one of the best therapeutic options available for infections caused ... ...

    Abstract Ceftazidime-avibactam (CZA) is one of the best therapeutic options available for infections caused by
    Mesh-Begriff(e) Humans ; Anti-Bacterial Agents/pharmacology ; Bacterial Proteins/genetics ; Bacterial Proteins/metabolism ; beta-Lactamases/genetics ; beta-Lactamases/metabolism ; Ceftazidime/pharmacology ; Drug Combinations ; Klebsiella Infections/microbiology ; Klebsiella pneumoniae/drug effects ; Klebsiella pneumoniae/isolation & purification ; Meropenem ; Drug Resistance, Multiple, Bacterial
    Chemische Substanzen Anti-Bacterial Agents ; avibactam, ceftazidime drug combination ; Bacterial Proteins ; beta-Lactamases (EC 3.5.2.6) ; Ceftazidime (9M416Z9QNR) ; Drug Combinations ; Meropenem (FV9J3JU8B1)
    Sprache Englisch
    Erscheinungsdatum 2023-01-05
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2619676-1
    ISSN 2235-2988 ; 2235-2988
    ISSN (online) 2235-2988
    ISSN 2235-2988
    DOI 10.3389/fcimb.2022.1010979
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Artikel: Overview of the Clinical and Molecular Features of Legionella Pneumophila: Focus on Novel Surveillance and Diagnostic Strategies.

    Gattuso, Giuseppe / Rizzo, Roberta / Lavoro, Alessandro / Spoto, Vincenzoleo / Porciello, Giuseppe / Montagnese, Concetta / Cinà, Diana / Cosentino, Alessia / Lombardo, Cinzia / Mezzatesta, Maria Lina / Salmeri, Mario

    Antibiotics (Basel, Switzerland)

    2022  Band 11, Heft 3

    Abstract: Legionella ... ...

    Abstract Legionella pneumophila
    Sprache Englisch
    Erscheinungsdatum 2022-03-09
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article ; Review
    ZDB-ID 2681345-2
    ISSN 2079-6382
    ISSN 2079-6382
    DOI 10.3390/antibiotics11030370
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  4. Artikel ; Online: In vitro evidence of the synergistic interaction of ceftopibrole and other antibiotics against multidrug-resistant Gram-negative isolates.

    Aprile, Ausilia / Caio, Carla / Gona, Floriana / Stefani, Stefania / Mezzatesta, Maria Lina

    Diagnostic microbiology and infectious disease

    2019  Band 95, Heft 4, Seite(n) 114884

    Abstract: The purpose of the present study was to investigate the in vitro activity of ceftobiprole in combination with other antimicrobials against 27 selected Gram-negative isolates, including ESBL-producing E. coli and KPC-OXA-48-producing K. pneumoniae. ... ...

    Abstract The purpose of the present study was to investigate the in vitro activity of ceftobiprole in combination with other antimicrobials against 27 selected Gram-negative isolates, including ESBL-producing E. coli and KPC-OXA-48-producing K. pneumoniae. Ceftobiprole activity in combination with amikacin, colistin, levofloxacin, piperacillin/tazobactam and rifampin was evaluated by time-kill curves and gradient-cross method (except colistin). Among the 27 strains tested with gradient strips most were resistant to ceftobiprole. Synergy was observed in some cases with piperacillin/tazobactam. There was at least one synergistic combination towards 9 isolates belonging to different species. No antagonism was observed with any of the antibiotic tested. In time-kill curves, performed for 12 selected isolates, synergistic interaction was more frequent, occurring with 32/60 combinations. The most interesting results of our study are the bactericidal effects of ceftobiprole in combination with colistin or piperacillin/tazobactam tested against Gram-negative isolates, including KPC and OXA-48-producing K. pneumoniae.
    Mesh-Begriff(e) Anti-Bacterial Agents/pharmacology ; Cephalosporins/pharmacology ; Drug Resistance, Multiple, Bacterial/drug effects ; Drug Synergism ; Gram-Negative Bacteria/drug effects ; Gram-Negative Bacteria/enzymology ; Gram-Negative Bacteria/isolation & purification ; Gram-Negative Bacterial Infections/microbiology ; Humans ; Microbial Sensitivity Tests ; Microbial Viability/drug effects ; beta-Lactamases/metabolism
    Chemische Substanzen Anti-Bacterial Agents ; Cephalosporins ; ceftobiprole (5T97333YZK) ; beta-Lactamases (EC 3.5.2.6)
    Sprache Englisch
    Erscheinungsdatum 2019-08-07
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 604920-5
    ISSN 1879-0070 ; 0732-8893
    ISSN (online) 1879-0070
    ISSN 0732-8893
    DOI 10.1016/j.diagmicrobio.2019.114884
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  5. Artikel: In Vitro Activity of Sulbactam-Durlobactam against Carbapenem-Resistant

    Segatore, Bernardetta / Piccirilli, Alessandra / Cherubini, Sabrina / Principe, Luigi / Alloggia, Giovanni / Mezzatesta, Maria Lina / Salmeri, Mario / Di Bella, Stefano / Migliavacca, Roberta / Piazza, Aurora / Meroni, Elisa / Fazii, Paolo / Visaggio, Daniela / Visca, Paolo / Cortazzo, Venere / De Angelis, Giulia / Pompilio, Arianna / Perilli, Mariagrazia

    Antibiotics (Basel, Switzerland)

    2022  Band 11, Heft 8

    Abstract: In the present study, the in vitro activity of the sulbactam-durlobactam (SUL-DUR) combination was evaluated against 141 carbapenem- ... ...

    Abstract In the present study, the in vitro activity of the sulbactam-durlobactam (SUL-DUR) combination was evaluated against 141 carbapenem-resistant
    Sprache Englisch
    Erscheinungsdatum 2022-08-22
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article
    ZDB-ID 2681345-2
    ISSN 2079-6382
    ISSN 2079-6382
    DOI 10.3390/antibiotics11081136
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  6. Artikel: Extensively drug-resistant ArmA-producing Acinetobacter baumannii in an Italian intensive care unit.

    Caio, Carla / Maugeri, Gaetano / Zingali, Tiziana / Gona, Floriana / Stefani, Stefania / Mezzatesta, Maria Lina

    The new microbiologica

    2018  Band 41, Heft 2, Seite(n) 159–161

    Abstract: We describe the spread of 12 carbapenem-resistant Acinetobacter baumannii isolates in hospitalized patients. All strains showed an extensively drug-resistant phenotype and high-level of aminoglycoside resistance, harboring the ArmA gene and blaoxa-23 ... ...

    Abstract We describe the spread of 12 carbapenem-resistant Acinetobacter baumannii isolates in hospitalized patients. All strains showed an extensively drug-resistant phenotype and high-level of aminoglycoside resistance, harboring the ArmA gene and blaoxa-23 downstream of ISAba1 (transposon Tn2008 arrangement) where both were located on the chromosome. These strains carry a class 1 integron containing the gene cassette aacA4-catB8-aadA1. Molecular analysis revealed that all isolates belonged to the same sequence type (ST) 2 clone. The spread of ArmA-producing A. baumannii strains limit the treatment options showing the dramatic situation which requires novel therapies to limit high mortality rates.
    Mesh-Begriff(e) Acinetobacter Infections/microbiology ; Acinetobacter baumannii/drug effects ; Acinetobacter baumannii/genetics ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Bacterial Proteins/genetics ; Bacterial Proteins/metabolism ; Carbapenems/pharmacology ; Cross Infection/microbiology ; Drug Resistance, Multiple, Bacterial/genetics ; Humans ; Intensive Care Units ; Italy/epidemiology ; Microbial Sensitivity Tests
    Chemische Substanzen Anti-Bacterial Agents ; Bacterial Proteins ; Carbapenems
    Sprache Englisch
    Erscheinungsdatum 2018-04
    Erscheinungsland Italy
    Dokumenttyp Journal Article
    ZDB-ID 756168-4
    ISSN 1121-7138 ; 0391-5352
    ISSN 1121-7138 ; 0391-5352
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  7. Artikel: Colistin Resistant

    Cafiso, Viviana / Stracquadanio, Stefano / Lo Verde, Flavia / Gabriele, Giacoma / Mezzatesta, Maria Lina / Caio, Carla / Pigola, Giuseppe / Ferro, Alfredo / Stefani, Stefania

    Frontiers in microbiology

    2019  Band 9, Seite(n) 3195

    Abstract: Even though colistin-based treatment represents the antimicrobial-regimen backbone for the management of multidrug-resistant Gram-negative infections, colistin resistance is still rare, at least as a full resistance, ... ...

    Abstract Even though colistin-based treatment represents the antimicrobial-regimen backbone for the management of multidrug-resistant Gram-negative infections, colistin resistance is still rare, at least as a full resistance, in
    Sprache Englisch
    Erscheinungsdatum 2019-01-07
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article
    ZDB-ID 2587354-4
    ISSN 1664-302X
    ISSN 1664-302X
    DOI 10.3389/fmicb.2018.03195
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  8. Artikel ; Online: Combination of aztreonam, ceftazidime-avibactam and amikacin in the treatment of VIM-1 Pseudomonas aeruginosa ST235 osteomyelitis.

    Mularoni, Alessandra / Mezzatesta, Maria Lina / Pilato, Michele / Medaglia, Alice Annalisa / Cervo, Adriana / Bongiorno, Dafne / Aprile, Ausilia / Luca, Angelo / Stefani, Stefania / Grossi, Paolo

    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

    2021  Band 108, Seite(n) 510–512

    Abstract: We describe a challenging case of patient with metallo-beta-lactamase-producing Pseudomonas aeruginosa sternal osteomyelitis following aortic valve replacement with biological prosthesis. The strain exhibited a multidrug-resistance phenotype carrying the ...

    Abstract We describe a challenging case of patient with metallo-beta-lactamase-producing Pseudomonas aeruginosa sternal osteomyelitis following aortic valve replacement with biological prosthesis. The strain exhibited a multidrug-resistance phenotype carrying the bla
    Mesh-Begriff(e) Aged ; Amikacin/therapeutic use ; Anti-Bacterial Agents/therapeutic use ; Azabicyclo Compounds/therapeutic use ; Aztreonam/therapeutic use ; Ceftazidime/therapeutic use ; Debridement ; Drug Combinations ; Drug Resistance, Multiple, Bacterial/genetics ; Drug Therapy, Combination ; Female ; Humans ; Osteomyelitis/drug therapy ; Osteomyelitis/microbiology ; Osteomyelitis/surgery ; Pseudomonas Infections/drug therapy ; Pseudomonas Infections/surgery ; Pseudomonas aeruginosa
    Chemische Substanzen Anti-Bacterial Agents ; Azabicyclo Compounds ; Drug Combinations ; avibactam, ceftazidime drug combination ; Amikacin (84319SGC3C) ; Ceftazidime (9M416Z9QNR) ; Aztreonam (G2B4VE5GH8)
    Sprache Englisch
    Erscheinungsdatum 2021-06-04
    Erscheinungsland Canada
    Dokumenttyp Case Reports
    ZDB-ID 1331197-9
    ISSN 1878-3511 ; 1201-9712
    ISSN (online) 1878-3511
    ISSN 1201-9712
    DOI 10.1016/j.ijid.2021.05.085
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  9. Artikel: In vitro activity of fosfomycin trometamol and other oral antibiotics against multidrug-resistant uropathogens

    Mezzatesta, Maria Lina / Andrea Novelli / Carla Caio / Gaetano Maugeri / Giulia La Rosa / Stefania Stefani / Tiziana Zingali

    International journal of antimicrobial agents. 2017 June, v. 49, no. 6

    2017  

    Abstract: Clinical midstream and urinary catheter isolates (n = 106) of extended-spectrum β-lactamase (ESBL)-positive Escherichia coli, Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae, Proteus mirabilis and meticillin-resistant ... ...

    Abstract Clinical midstream and urinary catheter isolates (n = 106) of extended-spectrum β-lactamase (ESBL)-positive Escherichia coli, Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae, Proteus mirabilis and meticillin-resistant Staphylococcus saprophyticus were tested against fosfomycin using the agar dilution method, the broth microdilution method and the gradient test described by the Clinical and Laboratory Standards Institute. Nitrofurantoin, co-trimoxazole, amoxicillin/clavulanic acid, cefuroxime, levofloxacin and ciprofloxacin were tested using the gradient test alone. Breakpoints from the European Committee on Antimicrobial Susceptibility Testing 2015 guidelines were used. Fosfomycin inhibited all of the ESBL-positive E. coli, P. mirabilis and meticillin-resistant S. saprophyticus strains isolated from urine, as well as 82% of KPC-producing K. pneumoniae isolates. Substantial agreement for fosfomycin activity was found for the three test methods, particularly for Enterobacteriaceae. This study confirmed that fosfomycin has good in vitro activity against more common multidrug-resistant uropathogens. Fosfomycin could be a reliable empirical therapeutic option for uncomplicated urinary tract infections caused by these organisms, and a valid option for sparing parenteral antibiotics, such as carbapenems.
    Schlagwörter amoxicillin ; antibacterial properties ; antibiotic resistance ; beta-lactamase ; carbapenems ; catheters ; cefuroxime ; ciprofloxacin ; Escherichia coli ; fosfomycin ; guidelines ; Klebsiella pneumoniae ; levofloxacin ; minimum inhibitory concentration ; multiple drug resistance ; nitrofurantoin ; Proteus mirabilis ; Staphylococcus saprophyticus ; urinary tract diseases ; urine
    Sprache Englisch
    Erscheinungsverlauf 2017-06
    Umfang p. 763-766.
    Erscheinungsort Elsevier B.V.
    Dokumenttyp Artikel
    ZDB-ID 1093977-5
    ISSN 1872-7913 ; 0924-8579
    ISSN (online) 1872-7913
    ISSN 0924-8579
    DOI 10.1016/j.ijantimicag.2017.01.020
    Datenquelle NAL Katalog (AGRICOLA)

    Zusatzmaterialien

    Kategorien

  10. Artikel ; Online: Emergence of two novel sequence types (3366 and 3367) NDM-1- and OXA-48-co-producing K. pneumoniae in Italy.

    Gona, Floriana / Bongiorno, Dafne / Aprile, Ausilia / Corazza, Erika / Pasqua, Betta / Scuderi, Maria Grazia / Chiacchiaretta, Matteo / Cirillo, Daniela Maria / Stefani, Stefania / Mezzatesta, Maria Lina

    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology

    2019  Band 38, Heft 9, Seite(n) 1687–1691

    Abstract: The aim of this study was to analyze the alarming spread of NDM-1- and OXA-48-co-producing Klebsiella pneumoniae clinical isolates, collected between October 2016 and January 2018 in a neonatal intensive care unit of the University Hospital, Catania, ... ...

    Abstract The aim of this study was to analyze the alarming spread of NDM-1- and OXA-48-co-producing Klebsiella pneumoniae clinical isolates, collected between October 2016 and January 2018 in a neonatal intensive care unit of the University Hospital, Catania, Italy, through whole genome sequencing. All confirmed carbapenem-resistant K. pneumoniae (CRKp) isolates were characterized pheno- and geno-typically, as well as by whole genome sequencing (WGS). A total of 13 CRKp isolates were identified from 13 patients. Pulsed-field gel electrophoresis (PFGE) was performed, and the multilocus sequence typing (MLST) scheme used was based on the gene sequence as published on the MLST Pasteur website. Core genome MLST (cgMLST) was also performed. All isolates co-carried bla
    Mesh-Begriff(e) Anti-Bacterial Agents/pharmacology ; Bacterial Proteins/genetics ; Bacterial Typing Techniques ; Carbapenems/pharmacology ; Disease Outbreaks ; Electrophoresis, Gel, Pulsed-Field ; Humans ; Infant, Newborn ; Intensive Care, Neonatal ; Italy ; Klebsiella Infections/microbiology ; Klebsiella pneumoniae/drug effects ; Klebsiella pneumoniae/enzymology ; Klebsiella pneumoniae/genetics ; Microbial Sensitivity Tests ; Multilocus Sequence Typing ; Whole Genome Sequencing ; beta-Lactamases/genetics
    Chemische Substanzen Anti-Bacterial Agents ; Bacterial Proteins ; Carbapenems ; beta-Lactamases (EC 3.5.2.6) ; beta-lactamase NDM-1 (EC 3.5.2.6) ; oxacillinase (EC 3.5.2.6)
    Sprache Englisch
    Erscheinungsdatum 2019-06-05
    Erscheinungsland Germany
    Dokumenttyp Journal Article
    ZDB-ID 603155-9
    ISSN 1435-4373 ; 0934-9723 ; 0722-2211
    ISSN (online) 1435-4373
    ISSN 0934-9723 ; 0722-2211
    DOI 10.1007/s10096-019-03597-w
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang